The Colby Management Team has many years of experience in Phase I/II/III clinical drug development and is lead by CEO David Zarling PhD MBA, previously CEO of Pangene Corp (PGC), a drug & target validation and services spin-out company from SRI International.
CSO Hirak Basu PhD has expertise in Phase I/II Oncology drug development and was formerly Associate Director of Oncology Drug R&D at Slil Biomed Corp, where he brought two drugs into clinical trials.
Minesh Mehta MD is Chief Medical Officer and has successfully led international Phase I/II/III Clinical Oncology trials. Recently he was chief strategic clinical advisor for TomoTherapy (TTPY), which completed its IPO in 2007.
Anne Vallerga MA PhD is Vice President Contracts & Grants and was an Institutional Review Board Manager at Stanford University Medical School.
The Colby Scientific Advisory Board includes the world-renowned prostate cancer clinician, George Wilding MD, UWCCC; synthetic organic chemist, Richard Zare PhD, Stanford Chemistry Chairman and internationally acclaimed oncology expert, Hasan Mukhtar PhD, UWCCC.
